Meril Life Sciences, a global leader in med-tech innovation, showcased its latest breakthrough, the Myval Octapro Transcatheter Heart Valve (THV), at GISE 2024 in Italy and the PCR London Valves 2024 conference. The company’s revolutionary innovation highlights its commitment to advancing cardiovascular and structural heart care.
The Myval Octapro THV builds on the success of Meril’s Myval series, recognized for transforming transcatheter aortic valve replacement (TAVR) procedures. Key features of the Octapro include reduced frame foreshortening for enhanced control, precise deployment, and a versatile size range to accommodate various patient anatomies.
Dr. John Jose, a leading cardiologist at CMC Vellore, lauded the technology, saying, “The Octapro retains the hallmark features of the Myval series while introducing significant advancements. Its superior clinical performance is set to redefine aortic stenosis treatment.”
At PCR London Valves, Meril also presented findings from the LANDMARK trial, published in the EuroIntervention Journal, confirming the Myval THV’s non-inferiority to competitors like Sapien and Evolut within 30 days post-implantation. The results underscore its safety and efficacy, further cementing its position in global TAVR solutions.
Sanjeev Bhatt, Senior VP of Corporate Strategy at Meril, stated, “The global recognition of the Myval Octapro THV is a testament to our dedication to innovation in structural heart care. We are honored to partner with clinicians worldwide to improve patient outcomes.”
With this achievement, Meril solidifies its role as a pioneer in structural heart solutions, committed to transforming lives through innovation.
.jpg)
Comment List